BCCIP as a prognostic marker for radiotherapy of laryngeal cancer

Radiotherapy and Oncology

Volumn 90, Issue 2, 2009, Pages 183-188

  Rewari, Amar ^a,b   Lu, Huimei ^b   Parikh, Rahul ^b   Yang, Qifeng ^b   Shen, Zhiyuan ^b   Haffty, Bruce G ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

BCCIP; Larynx cancer; Local recurrence; P53; Radiation therapy

Indexed keywords

BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FRACTIONATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNGEAL BIOPSY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; TIME SERIES ANALYSIS; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM-BINDING PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 59649109382     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.10.020     Document Type: Article

References (28)

1. American Cancer Society. Cancer facts and figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. Fremgen A.M., Bland K.I.., McGinnis Jr. L.S., et al. Clinical highlights from the National Cancer Data Base, 1999. CA Cancer J Clin 49 (1999) 145-158
3. Franchin G., Minatel E., Gobitti C., et al. Radiation treatment of glottic squamous cell carcinoma, stage I and II: analysis of factors affecting prognosis. Int J Radiat Oncol Biol Phys 40 (1998) 541-548
4. Rudoltz M.S., Benammar A., and Mohiuddin M. Prognostic factors for local control and survival in T1 squamous cell carcinoma of the glottis. Int J Radiat Oncol Biol Phys 26 (1993) 767-772
5. Mendenhall W.M., Werning J.W., Hinerman R.W., et al. Management of T1-T2 glottic carcinomas. Cancer 100 (2004) 1786-1792
6. Franchin G., Minatel E., Gobitti C., et al. Radiotherapy for patients with early-stage glottic carcinoma: univariate and multivariate analyses in a group of consecutive, unselected patients. Cancer 98 (2003) 765-772
7. Milas L., Mason K.A., Hunter N., et al. Chemoradiotherapy emerging treatment improvement strategies. Head Neck 25 (2003) 152-167
8. Hollstein M., Sidransky D., Vogelstein B., et al. P53 mutations in human cancers. Science 253 (1991) 49-53
9. Schwartz J.L., Rasey J., Wiens L., et al. Functional inactivation of p53 by HPV-E6 transformation is associated with a reduced expression of radiation-induced potentially lethal damage. Int J Radiat Oncol Biol Phys 75 (1999) 285-291
10. Jimenez G.S., Nister M., Stommel J.M., et al. A transactivation-deficient monoe model provides insight into Trp53 regulation and function. Nat Genet 26 (2000) 37-43
11. Vogelstein B., Lane D., Levine A.J., et al. Surfing the p53 network. Nature 408 (2000) 307-310
12. Hollstein M., Rice K., Greenblatt M.S., et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22 (1994) 3551-3555
13. Jacks T., Remington L., Williams B.O., et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 4 (1994) 1-7
14. Meng X., Yue J., Liu Z., et al. Abrogation of the transactivation activity of p53 by BCCIP down-regulation. J Biol Chem 282 (2007) 1570-1576
15. Rimm D.L., Camp R.L., Charette L.A., et al. Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol 70 (2001) 255-264
16. Chen B., Van den Brekel M.W., Buschers W., et al. Validation of tissue array technology in head and neck squamous cell carcinoma. Head Neck 25 (2003) 922-930
17. Jourdan F., Sebbagh N., Comperat E., et al. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 443 (2003) 115-121
18. Leversha M.A., Fielding P., Watson S., et al. Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays. J Pathol 200 (2003) 610-619
19. Liu J., Yuan Y., Huan J., et al. Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionary conserved nuclear protein that interacts with BRCA2. Oncogene 20 (2001) 336-345
20. Maestro R., Dolcetti R., Gasparotto D., et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 7 (1992) 1159-1166
21. Medini E., Medini A., Gapany M., et al. Radiation therapy in early carcinoma of the glottic larynx T1N0M0. Int J Radiat Oncol Biol Phys 36 (1996) 1211-1213
22. Mendenhall W.M., Amdur R.J., Morris C.G., et al. T1-T2N0 squamous cell carcinoma of the gottic larynx treated with radiation therapy. J Clin Oncol 19 (2001) 4029-4036
23. Yamazaki H., Nishiyama K., Tanaka E., et al. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 64 (2006) 77-82
24. Meng X., Fan J., Shen Z., et al. Roles of BCCIP in chromosome stability and cytokinesis. Oncogene 26 (2007) 6253-6260
25. Lu H., Yue J., Meng X., et al. BCCIP regulates homologues recombination by distinct domains and suppresses spontaneous DNA damage. Nucleic Acids Res 35 (2007) 7160-7170
26. Lu H., Guo X., Meng X., et al. The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair. Mol Cell Biol 25 (2005) 1949-1957
27. Soussi T., and Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331 (2005) 834-842
28. Soussi T., Kato S., Levy P.P., et al. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 25 (2005) 6-17